TWD
XENE icon

True Wealth Design’s Xenon Pharmaceuticals XENE Stock Holding History

True Wealth Design’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-9
Closed -$302 – 2846
2025
Q1 		$302 Buy
+9
New +$342 ﹤0.01% 1772

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

True Wealth Design's XENE Position: Q2 2025 in Review

True Wealth Design sold out of Xenon Pharmaceuticals (XENE) in Q2 2025, closing a stake of 9 shares — an estimated $302 sold.

True Wealth Design first reported a position in XENE in Q1 2025 and held it in 1 quarter. The position peaked at $302 in Q1 2025. 206 funds tracked by Wall St. Rank hold XENE as of Q2 2025.

  • True Wealth Design reported no remaining Xenon Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • True Wealth Design sold 9 Xenon Pharmaceuticals shares in Q2 2025, an estimated $302.
  • True Wealth Design first reported a position in Xenon Pharmaceuticals in Q1 2025 and held it in 1 quarter.
  • True Wealth Design's Xenon Pharmaceuticals position peaked at $302 in Q1 2025.
  • 206 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2025.

Based on True Wealth Design's 13F filing for Q2 2025, filed 6 Aug 2025.